Sangamo Therapeutics (SGMOQ) Income from Continuing Operations (2010 - 2025)

Sangamo Therapeutics' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 37419000.0 for Q4 2025.

• On a quarterly basis, Income from Continuing Operations fell 59.94% year-over-year to 37419000.0 in Q4 2025; TTM through Dec 2025 was 122932000.0, a 25.52% decrease from a year earlier, with the FY2025 full-year figure at 122932000.0, down 25.52% from the prior year.
• Income from Continuing Operations eased to 37419000.0 in Q4 2025 per SGMOQ's latest filing, from 34930000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 21133000.0 in Q1 2023 and bottomed at 114506000.0 in Q2 2023.
• The 5-year median for Income from Continuing Operations is 43575000.0 (2022), against an average of 42463150.0.
• Across the five-year window, Income from Continuing Operations tumbled 3063.26% in 2021 and surged 148.05% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 37496000.0 in 2021, then tumbled by 38.53% to 51943000.0 in 2022, then fell by 16.08% to 60295000.0 in 2023, then soared by 61.2% to 23396000.0 in 2024, then tumbled by 59.94% to 37419000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Income from Continuing Operations figures stand at 37419000.0 (Q4 2025), 34930000.0 (Q3 2025), and 19986000.0 (Q2 2025).